Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Combined Pathologies in FTLD-TDP Types A and C.
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).
Splice epitranscriptomics and DNA damage repair together: ALKBH5-m6A-SF3B1 regulation in leukemic transformation.
Deciding Under Uncertainty: The Case of Refractory Intracranial Hypertension.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Deciding Under Uncertainty: The Case of Refractory Intracranial Hypertension.
Deciding Under Uncertainty: The Case of Refractory Intracranial Hypertension. Front Neurol. 2020; 11:908.
View in:
PubMed
authors with profiles
Christos Lazaridis